ASX Announcement |14 August 2020
Noxopharm Limited ASX:NOX

Noxopharm August 2020 EGM Corporate Presentation

Australian clinical stage drug development company Noxopharm (ASX:NOX) is pleased to provide to shareholders and the market generally the corporate presentation for today's Extraordinary General Meeting (EGM).

Following voting formalities, the Company will take the opportunity to present this corporate presentation and an update on recent progress in its R&D activities and plans for upcoming clinical trials that were the subject of the recent capital raise. Noxopharm's CEO and Founder (Dr Graham Kelly) and CMO (Dr Gisela Mautner) will present the update virtually.

This presentation can be found at: https://www.noxopharm.com/site/investors/presentations

---

About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body's immune system to inflict damage on cancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Veyonda® also is to undergo evaluation as a treatment for septic shock, starting with a Phase 1 study in patients with moderate COVID-19 disease.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).

To learn more please visit: https://www.noxopharm.com/

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries
Julia Maguire
The Capital Network

E: julia@thecapitalnetwork.com.au
T: + 61 2 8999 3699

Graham Kelly, CEO and Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm EGM – August 2020 Presentation

Noxopharm Limited (ASX:NOX)

Graham Kelly - Executive Chairman and CEO

Veyonda®

NOXOPHARM

DISCOVER DEVELOP DELIVER

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Immuno-oncology (I-O) drugs have taken the oncology world by storm and are the future of cancer therapy

- Current market for I-O drugs
  = ~**A$30 billion** p.a. (2019)
- I-O drugs currently limited in use
  Potential market predicted to be **>A$150 billion** p.a.

NOX believes that **Veyonda®** will be one of the main drugs driving that **A$120 billion** increase in I-O use and value

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

This presentation .....

1. Who We Are

2. Veyonda® Explained

3. Our Business

4. Investment Case

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

01 Who we are

© 2020 Noxopharm Ltd. All rights reserved.

Who We Are

- Australian clinical-stage drug development company
- ASX: NOX [listed Aug 2016]
- Focus on large markets of unmet need – cancer and septic shock
- Commercial goal of out-licensing at Phase 2 stage
- Veyonda® - a major commercial opportunity with 'blockbuster' potential

A disruptive technology transforming the management of cancer

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

First-in-class

02 Veyonda® explained

Dual oncotoxic and immuno-oncology drug

© 2020 Noxopharm Ltd. All rights reserved.

Veyonda® Explained

First-in-class anti-cancer drug with unique 3-step action

Oncotoxic



Kills cancer cells.
Unique action sparing most healthy cells

Step 1

Immuno-oncology effects



Activates cancer-fighting immune cells (T-cells)

Step 2



Enables cancer-fighting immune cells to enter tumour and kill remaining cancer cells

Step 3

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Veyonda® Explained

Increasing I-O therapy effectiveness depends on boosting the number of cancer-fighting cells inside tumours. Referred to as converting tumours from COLD to HOT



Majority of human tumours are COLD:

- No active immune cells present
- Believed to be a major cause of limited effectiveness of current cancer therapies

Converting human tumours to HOT:

- Increased immune function
- Increased effectiveness of chemotherapy, radiotherapy and immuno-oncology therapy

COLD to HOT conversion current major goal of pharma industry
Limited success to date
Noxopharm believes Veyonda® will be the 'breakthrough' drug

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

ONCOLOGY

03 Our Business

SEPTIC SHOCK

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

Clinical Objective

To see Veyonda® come to market as a well-tolerated, cost-effective, immuno-oncology (I-O) drug assisting immune checkpoint inhibitors, radiotherapy and chemotherapy to work more effectively across most forms of cancer

Commercial Objective

To provide comprehensive pre-clinical and clinical data packages that are compelling for 'blockbuster' trade deals

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

Aiming to show an I-O benefit four different ways

Higher priority

- **DARRT** — Veyonda® + external beam radiotherapy
- **IONIC** — Veyonda® + immune checkpoint inhibitor

Lower priority

- **LuPIN** — Veyonda® + ^{177}Lu-PSMA radiotherapy
- **CEP** — Veyonda® + chemotherapy

Rationale:

- risk mitigation
- unlikely 1 size fits all approach in all cancers and all patients
- increased asset value based on **unique multiple market opportunities**

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

DARRT

DARRT is our #1 priority program



COLD ➡ HOT effect

- Known as an '**abscopal response**'. Normally an extremely rare event
- DARRT aiming to make abscopal responses commonplace

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

DARRT

DARRT is our #1 priority program

Aimed at the largest sector in the oncology market

- End-stage cancer where treatment is limited to palliative care
- Little competition
- Multi-billion dollar market opportunity

Attractive form of anti-cancer therapy

- Well-tolerated, short-course of therapy in out-patient clinic
- Most common form of radiotherapy (= low cost, ready availability)

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

DARRT

Seeking proof-of-principle in **end-stage prostate cancer**



Course of Disease and Treatment Journey for Stage I - IV Prostate Cancer

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

DARRT

DARRT-1 Phase 1b study

25 men with end-stage prostate cancer who had stopped responding to treatment, with metastatic and progressive disease, and were considered to have limited life-spans

- **Clear evidence of an I-O effect**
- 16 men completed the 14 days of treatment and the 6-month follow up period
- In 10 men, tumours had stopped growing or were reduced in size
- **Abscopal responses confirmed in 4 men***
- Treatment well tolerated

* First known demonstration of abscopal responses in prostate cancer in more than isolated cases

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and oncology

IONIC

IONIC study is our #2 priority program

Immune checkpoint inhibitors

- Keytruda (Merck); Opdivo & Yervoy (BMS)
- Minority of cancers are responsive cancers (eg. melanoma, lung, kidney, bladder)
- Majority of cancers non-responsive (eg. breast, prostate, ovarian, bowel)
- Nevertheless, 2019 global sales ~**A$30 billion**
- Achieving responses in majority of cancers estimated to yield market worth **>A$150 billion p.a.**

Objective = by converting tumours from COLD to HOT, to use Veyonda to boost the response rates to immune checkpoint inhibitors and make Veyonda a key contributor to the ~A$120 billion missing market opportunity

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

And then came SARS-CoV-2 ……



and the pandemic ……..

and with it, an unexpected opportunity……..

the possibility of having an effective therapy for SEPTIC SHOCK

Our Business – Veyonda® and septic shock

SEPTIC SHOCK

SEPTIC SHOCK: ONE OF THE SINGLE LARGEST CAUSES OF DEATH IN THE WORLD

- An estimated 10 million people die each year in the world from septic shock. That is about 20% of all human deaths
- An estimated minimum of 5000 people die from SEPTIC SHOCK each year in Australia

- SEPTIC SHOCK occurs when the body produces an excessively high immune/inflammatory response to infection (viral, bacterial) or trauma (accidents, major surgery)
- That hyper-response produces something called a **CYTOKINE STORM** resulting in multiple organ failure. This is known as **SEPTIC SHOCK**
- **SEPTIC SHOCK** is invariably fatal because we lack effective therapies

- Up to this year, the most common viral cause of SEPTIC SHOCK in Australia was seasonal influenza with up to about 3,000 deaths p.a.
- **In 2020, a new viral cause has emerged** **SARS-CoV-2 virus**

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and septic shock

NOXCOVID

First clinical trial of a STING blocker in COVID-19 patients



Cytokine Storm

- Septic shock is triggered by a **CYTOKINE STORM**
- About 5% of COVID-19 patients develop a **CYTOKINE STORM**
- **CYTOKINE STORM** results in clotting and organ failure
- **CYTOKINE STORM** is associated with excessive STING signaling
- **Veyonda only known inhibitor of STING signaling in the clinic**

NOXCOVID study

- Phase 1 (pilot) study in patients with moderate to severe illness
- 30-40 patients
- Objectives: safety, biomarkers (cytokines), clinical responses

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Our Business – Veyonda® and septic shock

NOXCOVID

SEPTIC SHOCK

Q. You have explained that Veyonda is working as an anti-cancer drug by promoting the immune system. If septic shock is driven by an immune system that is already over-active, wouldn't Veyonda just make things worse?

A. Yes it could, if it wasn't for the fact that one of the special and unique features of Veyonda is that it only works on systems behaving abnormally, restoring their function to normal

- In cancer, the abnormality is a suppressed immune system. Veyonda restores this function to normal by activating it
- In septic shock, the abnormality is an over-active immune system. Veyonda restores this function to normal by reducing it

Veyonda is the only drug that blocks the main source of a CYTOKINE STORM that is already in the clinic and proven to be well-tolerated

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Large commercial opportunities

Areas of major M&A activity

Strong news flow

04 Investment case

Focused commercial strategy

Experienced executive and Board

© 2020 Noxopharm Ltd. All rights reserved.

Investment case

Major market opportunities

DARRT

- Focus on end-stage prostate cancer
- Estimated 300,000 deaths globally; 33,000 in the U.S.
- **Aiming to make Veyonda standard of care with radiotherapy in end-stage prostate cancer**

IONIC

- Checkpoint inhibitor 2019 sales = A$30 billion
- Potential market estimated >A$150 billion p.a.
- **Aiming to make Veyonda the go-to drug to increase response rates to immune checkpoint inhibitors**

SEPTIC SHOCK

- Septic shock is major cause of death globally; responsible for estimated 20% of all human deaths
- Associated with viral and bacterial infections; trauma
- No effective treatment. Value of market unknown, but expected to be $multi-billion
- **Aiming to develop a treatment, based on Veyonda, that will reduce death and long-term disability in COVID-19 patients**

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Investment case

Prostate cancer major area of M&A activity

DARRT

LuPIN

Recent acquisitions	Buyer	Seller	Price range
XTANDI® mCRPC (2016)	Pfizer	MEDIVATION	US$14 billion
^{177}Lu-PSMA-617 mCRPC (2018)	NOVARTIS	ENDOCYTE	US$2.1 billion
^{177}Lu-PSMA-617 & others mCRPC (2018)	NOVARTIS	Advanced Accelerator Applications	US$3.9 billion

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Investment Case

Multiple programs = multiple catalysts Q3 20 - Q1 21

DARRT

- Phase 2 multi-national study in ~200 men; DARRT-2
- Anticipated start Q1 2021
- Pending appointment of CRO

LuPIN

- Imminent - last patient final treatment
- Imminent - publication of data from first 32 men
- Anticipated conference updates on remaining 24 men

IONIC

- Logistical planning current
- Anticipated start Q1 2021

NOXCOVID

- Aiming to enrol first patient Q3 2020
- Aiming to complete enrolment Q4 2020, with results expected in Q1 2021

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Investment Case

Focused Commercial Strategy

Attract potential partners by continuing to undertake clinical trials to develop Veyonda® as standard of care in treatment of end-stage prostate cancer	DARRT-2 Phase 2 data LuPIN Phase 2 data
Position Veyonda® as a major opportunity to increase response rates to immune checkpoint inhibitors	IONIC study
Position Veyonda® as a potential COVID-19 treatment preventing progression of patients onto requiring ICU care and mechanical ventilation	NOXCOVID Phase 1 study

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Executive Team



Dr Graham Kelly -
Executive Chairman and CEO

Jeanette Bell
Chief Operating Officer

Dr Gisela Mautner
Chief Medical Officer

Shawn Van Boheemen
Chief Financial Officer

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Key metrics

Number of Shares	213.2 million shares outstanding
Board shareholding	19.8%
SP (13 Aug 2020) Listing date	A$0.32 9 August 2016
Market cap (13 Aug 2020)	A$67.16 M
Cash position	• AU$ 7.1M (30 June 2020)

NOXOPHARM

© 2020 Noxopharm Ltd. All rights reserved.

Learn more about Noxopharm Limited (ASX:NOX)

https://www.noxopharm.com
Email: info@noxopharm.com
Phone: (+61) 2 9144 2223
https://www.linkedin.com/company/noxopharm-limited
https://twitter.com/noxopharm

Media Enquiries
The Capital Network
Julia Maguire
+61 2 8999 3699
julia@thecapitalnetwork.com.au